

# WeedMD Inc

10:15 14 Jul 2020

## WeedMD says its cannabis products included in University Health Network national study

WeedMD Inc (CVE:WMD) (OTCQX:WDDMF) announced Tuesday that its products and strains have been included in University Health Networks' (UNH) Medical Cannabis Real-World Evidence study.

UNH is launching nationwide clinical trials studying the effects of cannabis use on chronic pain, sleep issues, anxiety and depression.

Participating patients can select their medical cannabis products using the online portal created by Medical Cannabis by Shoppers Drug Mart. WeedMD is one of the first licensed producers (LPs) to have its products and strains included, the company said.

### READ: WeedMD works key amendments into existing credit facility

"Recognizing the importance of strain validation as cannabis products advance through Canada's medical and pharmaceutical channels is paramount for building trust and accountability in our industry, and we congratulate UHN, Shoppers and TruTrace on this breakthrough initiative," WeedMD CEO Angelo Tsebelis said in a statement.

WeedMD is also the only LP to have all its cannabis strains registered under TruTrace Technologies Inc's (CSE:TTT) (OTC:BKKSF) proprietary StrainSecure cannabis tracing and verification platform.

"As the only producer with all its products registered under StrainSecure, we are proud to be included," Tsebelis said. "Patients and their medical practitioners expect traceability, origin assurance and consistency in their medicine, particularly when used as a natural alternate for treating traumatic indications such as pain management — this study will present much needed evidence and we're looking forward to the results."

The study is being led by Hance Clarke, director of pain services at Toronto General Hospital.

"Shoppers Drug Mart is trusted by patients and healthcare providers to provide medical products that have been tested and validated, regardless of whether that medication came from a lab or a greenhouse," Shoppers VP of Business Development/Cannabis Strategy Ken Weisbrod said. "Many partners came together to launch this initiative and we are proud to work with industry leaders to further our ability to provide Canadians with safe, consistent, rigorously tested cannabis-based medication."

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 0.345

**Market Cap:** \$72.54 m

### 1 Year Share Price Graph



### Share Information

**Code:** WMD

**Listing:** TSX-V

**52 week High Low**  
0.85 0.225

**Sector:** Cannabis

**Website:** [www.weedmd.com](http://www.weedmd.com)

### Company Synopsis:

WeedMD Inc. is the publicly-traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc. , licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, ON as well as a fully-licensed 26,000 sq. ft.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of WeedMD Inc named herein, including the promotion by the Company of WeedMD Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).